Ajai Chari
- Hematology top 0.1%
- Molecular Biology top 2%
- Oncology top 1%
- Radiology, Nuclear Medicine and Imaging top 2%
- Immunology top 5%
- Co-authors
- Sundar JagannathSaad Z. UsmaniHearn Jay ChoSagar LonialKhalid MezziNina ShahEmma ScottAmrita Krishnan
- Topics
- Multiple Myeloma Research and Treatments (201 papers)Protein Degradation and Inhibitors (82 papers)Peptidase Inhibition and Analysis (38 papers)
- Cited by
- HematologyOncologyGenetics
- Journals
- New England Journal of MedicineJournal of Clinical OncologySHILAP Revista de lepidopterología
- Partner nations
- United StatesSpainNetherlands
In The Last Decade
Ajai Chari
205 papers receiving 4.6k citations
Hit Papers
Peers
Comparison fields: 5 of 125
- Hematology 3.4k
- Molecular Biology 2.7k
- Oncology 2.6k
- Radiology, Nuclear Medicine and Imaging 677
- Immunology 584
Countries citing papers authored by Ajai Chari
This map shows the geographic impact of Ajai Chari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ajai Chari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ajai Chari more than expected).
Fields of papers citing papers by Ajai Chari
This network shows the impact of papers produced by Ajai Chari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ajai Chari. The network helps show where Ajai Chari may publish in the future.
Co-authorship network of co-authors of Ajai Chari
This figure shows the co-authorship network connecting the top 25 collaborators of Ajai Chari. A scholar is included among the top collaborators of Ajai Chari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ajai Chari. Ajai Chari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 15 | |
| 2 | 0 | |
| 3 | 1 | |
| 4 | 2 | |
| 5 | 0 | |
| 6 | 56 | |
| 7 | Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States | 9 |
| 8 | 14 | |
| 9 | 18 | |
| 10 | 1 | |
| 11 | 2 | |
| 12 | 59 | |
| 13 | 8 | |
| 14 | 15 | |
| 15 | 9 | |
| 16 | 6 | |
| 17 | 23 | |
| 18 | 3 | |
| 19 | 2 | |
| 20 | 27 |
About Ajai Chari
Ajai Chari is a scholar working on Hematology, Genetics and Oncology, having authored 217 papers that have together received 4.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (201 papers), Protein Degradation and Inhibitors (82 papers) and Peptidase Inhibition and Analysis (38 papers). The work is most often cited by research in Hematology (3.4k citations), Oncology (2.6k citations) and Genetics (490 citations). Ajai Chari has collaborated with scholars based in United States, Spain and Netherlands. Frequent co-authors include Sundar Jagannath, Saad Z. Usmani, Hearn Jay Cho, Sagar Lonial, Khalid Mezzi, Nina Shah, Emma Scott, Amrita Krishnan, Samir Parekh and María‐Victoria Mateos. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.